Izencitinib induction treatment in patients with moderately-to-severely-active Crohn's Disease: A phase 2 double-blind, randomized, placebo-controlled study

被引：0
|
作者：
Schreiber, S. [1 ]
Reinisch, W. [2 ]
Nguyen, D. [3 ]
Guerin, T. [4 ]
Kierkus, J. [5 ]
Rozpondek, P. [6 ]
Bourdet, D. [3 ]
Abhyankar, B. [7 ]
Peyrin-Biroulet, L. [8 ]
机构：
[1] Univ Kiel, Univ Hosp Schleswig Holstein, Dept Internal Med I, Kiel, Germany
[2] Med Univ Vienna, Dept Internal Med III, Vienna, Austria
[3] Theravance Biopharma Inc, Res & Dev, San Francisco, CA USA
[4] Theravance Biopharma Ireland Ltd, Res & Dev, Dublin, Ireland
[5] Childrens Mem Hlth Inst, Dept Gastroenterol, Warsaw, Poland
[6] Krakow Med Ctr, Krakow, Poland
[7] Theravance Biopharma Ireland Ltd, Clin Dev, Dublin, Ireland
[8] Univ Lorraine, Nancy Univ Hosp, Dept Gastroenterol, Vandoeuvre Les Nancy, France
来源：
JOURNAL OF CROHNS & COLITIS | 2023年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P375
引用
收藏
页码：505 / 507
页数：3
相关论文
共 50 条
  • [1] IZENCITINIB INDUCTION TREATMENT IN PATIENTS WITH MODERATELY-TO-SEVERELY ACTIVE ULCERATIVE COLITIS: A PHASE 2B RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY
    Danese, Silvio
    Sandborn, William J.
    Peyrin-Biroulet, Laurent
    Nguyen, Deanna D.
    Guerin, Tadhg
    Rozpondek, Piotr
    Ganeshappa, Ravi
    Dubovyi, Vladyslav
    Bourdet, David
    Abhyankar, Brihad
    GASTROENTEROLOGY, 2022, 162 (07) : S964 - S964
  • [2] A randomized, double-blind, placebo-controlled trial of lenalidomide in the treatment of moderately severe active Crohn's disease
    Mansfield, J. C.
    Parkes, M.
    Hawthorne, A. B.
    Forbes, A.
    Probert, C. S. J.
    Perowne, R. C.
    Cooper, A.
    Zeldis, J. B.
    Manning, D. C.
    Hawkey, C. J.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2007, 26 (03) : 421 - 430
  • [3] Etrolizumab as induction and maintenance therapy in patients with moderately to severely active Crohn's disease (BERGAMOT): a randomised, placebo-controlled, double-blind, phase 3 trial
    Sandborn, William J.
    Panes, Julian
    Danese, Silvio
    Sharafali, Zaineb
    Hassanali, Azra
    Jacob-Moffatt, Rhian
    Eden, Christopher
    Daperno, Marco
    Valentine, John F.
    Laharie, David
    Baia, Carolina
    Atreya, Raja
    Panaccione, Remo
    Rydzewska, Grazyna
    Aguilar, Humberto
    Vermeire, Severine
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2023, 8 (01): : 43 - 55
  • [4] Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis - Results of a double-blind, randomized, placebo-controlled trial
    Mease, PJ
    Gladman, DD
    Ritchlin, CT
    Ruderman, EM
    Steinfeld, SD
    Choy, EHS
    Sharp, JT
    Ory, PA
    Perdok, RJ
    Weinberg, MA
    ARTHRITIS AND RHEUMATISM, 2005, 52 (10): : 3279 - 3289
  • [5] Etanercept for active Crohn's disease: A randomized, double-blind, placebo-controlled trial
    Sandborn, WJ
    Hanauer, SB
    Katz, S
    Safdi, M
    Wolf, DG
    Baerg, RD
    Tremaine, WJ
    Johnson, T
    Diehl, NN
    Zinsmeister, AR
    GASTROENTEROLOGY, 2001, 121 (05) : 1088 - 1094
  • [6] ETRASIMOD INDUCTION THERAPY IN MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE: RESULTS FROM A PHASE 2, RANDOMIZED, DOUBLE-BLIND SUBSTUDY
    D'Haens, Geert
    Dubinsky, Marla C.
    Peyrin-Biroulet, Laurent
    Danese, Silvio
    Sands, Bruce E.
    Wolf, Douglas C.
    Yarur, Andres J.
    Chiorean, Michael V.
    Dray, Danielle
    Modesto, Irene
    Tan, Huaming
    Gu, Guibao
    Lopez, Claudia
    Su, Chinyu
    Zhang, Jinkun
    McDonnell, Aoibhinn
    Schreiber, Stefan
    Feagan, Brian G.
    Vermeire, Severine
    GASTROENTEROLOGY, 2023, 164 (06) : S223 - S223
  • [7] A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Brodalumab in Patients With Moderate-to-Severe Crohn's Disease
    Targan, Stephan R.
    Feagan, Brian
    Vermeire, Severine
    Panaccione, Remo
    Melmed, Gil Y.
    Landers, Carol
    Li, Dalin
    Russell, Chris
    Newmark, Richard
    Zhang, Nan
    Chon, Yun
    Hsu, Yi-Hsiang
    Lin, Shao-Lee
    Klekotka, Paul
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2016, 111 (11): : 1599 - 1607
  • [8] Tamuzimod in patients with moderately-to-severely active ulcerative colitis: a multicentre, double-blind, randomised, placebo-controlled, phase 2 induction trial
    Sands, Bruce E.
    Panaccione, Remo
    D'Haens, Geert
    Schreiber, Stefan
    Jairath, Vipul
    Duvall, Aaron
    Kierkus, Jaroslaw
    Walczak, Michael
    Naik, Snehal
    Gilder, Kye
    Lindstrom, Beatriz
    Ogilvie, Kathleen
    Sandborn, William J.
    Vermeire, Severine
    Rubin, David
    Peyrin-Biroulet, Laurent
    Danese, Silvio
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2025, 10 (03): : 210 - 221
  • [9] Randomized, Double-blind, Placebo-Controlled Trial of Andrographis Paniculata Extract (HMPL-004) in Patients with Moderately Active Crohn's Disease
    Sandborn, William
    Targan, Stephan
    Byers, Vera
    Tang, Tom
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2010, 105 : S429 - S430
  • [10] Efficacy and Safety of Omilancor in a Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial of Patients With Crohn's Disease
    Chowla, Navreet M.
    Tariq, Raseen
    Aggarwal, Manik
    Loftus, Edward V.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (10): : S820 - S821
12345